<DOC>
	<DOCNO>NCT01413386</DOCNO>
	<brief_summary>Paclitaxel cover metal biliary stent non-inferior common cover metal biliary stent patency rate safety 6 month stenting .</brief_summary>
	<brief_title>Efficacy Safety Paclitaxel Eluting Covered Biliary Stent Common Covered Metallic Biliary Stent</brief_title>
	<detailed_description>Paclitaxel cover metal biliary stent ( Niti-S Mira-Cover II Biliary Stent ) non-inferior common cover metal biliary stent ( Niti-S Biliary Stent_ComVi type ) patency rate safety 6 month stenting .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient submit write informed consent trial , 18 ~ 90 year old Patient pancreatic cancer and/or biliary cancer mid distal CBD invasion Patient inoperable and/or unresectable case malignant pancreatic stenosis Patient attempt endoscopic biliary metallic stenting ( ERBD ) firstly Patient life expectancy least longer 3 month ( Karnofsky score &gt; 60 % ) Patient previously surgical biliary drainage Patient carry bleed disorder Patient combine Hilar and/or intrahepatic duct cancer Patient improper endoscopic treatment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>paclitaxel</keyword>
	<keyword>drug elute stent</keyword>
</DOC>